ProfileGDS5678 / 1421106_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 62% 63% 68% 75% 63% 62% 67% 64% 62% 62% 65% 66% 61% 62% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.7480962
GSM967853U87-EV human glioblastoma xenograft - Control 23.7408163
GSM967854U87-EV human glioblastoma xenograft - Control 34.1383968
GSM967855U87-EV human glioblastoma xenograft - Control 45.0948675
GSM967856U87-EV human glioblastoma xenograft - Control 53.7076363
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.7874662
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.1491167
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.8400264
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7087162
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.7021962
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.9273565
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.9725866
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.6761561
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.7164462